Stock Analiz

NRX Pharmaceuticals, Inc. NRXP

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$2.19Market cap $96M
Open the interactive analysis →

NRX Pharmaceuticals, Inc. (NRXP) is a healthcare company listed in the US with a market value of about $96M. In the twelve months to June 30, 2026 it had revenue of $3M and net income of -$23M, a net margin of -691.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -317%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About NRX Pharmaceuticals

NRX Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 2 of the last 8 years in our data. Its share count rose by 225% over three years (dilution for shareholders). It spends 308% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S28.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2336.5%
ROIC (5-yr avg.)-317.5%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$3M$1M$0$0—————
Net income-$23M-$29M-$25M-$30M-$40M-$93M-$52M$408427$66101
Free cash flow——-$11M-$22M-$40M-$38M-$2M——
EPS (diluted)$-0.55$-1.34$-2.36$-3.98$-6.00$-19.80$-15.10$-1.10$-2.90
Net margin-691.8%-2336.5%———————
ROIC————-195.3%-439.7%——-14.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is NRX Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does NRX Pharmaceuticals pay a dividend?

Not currently.

Is NRX Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. NRX Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.